ImmuPharma plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMM.L research report →
Companywww.immupharma.co.uk
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
- CEO
- Timothy Paul McCarthy
- IPO
- 2003
- Employees
- 5
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $23.60M
- P/E
- -7.80
- P/S
- 0.00
- P/B
- 66.91
- EV/EBITDA
- -10.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6634.51%
- ROIC
- -971.74%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,483,000 · 15.02%
- EPS
- $-0.01 · 25.93%
- Op Income
- $-2,280,000
- FCF YoY
- -29.78%
Performance & Tape
- 52W High
- $19.40
- 52W Low
- $1.39
- 50D MA
- $4.70
- 200D MA
- $7.08
- Beta
- 2.98
- Avg Volume
- 2.49M
Get TickerSpark's AI analysis on IMM.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IMM.L Coverage
We haven't published any research on IMM.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMM.L Report →